Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial-Reference-Cited by-同舟云学术

Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial

Published:2018-11-13 Issue:1 Volume:27 Page:75-86
ISSN:1930-7381
Container-title:Obesity
language:en
Short-container-title:Obesity

Author:

Wadden Thomas A.¹^ORCID,Walsh Olivia A.¹,Berkowitz Robert I.¹²,Chao Ariana M.¹³^ORCID,Alamuddin Naji⁴,Gruber Kathryn¹,Leonard Sharon¹,Mugler Kimberly¹,Bakizada Zayna¹,Tronieri Jena Shaw¹^ORCID

Affiliation:

1. Center for Weight and Eating Disorders, Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

2. Department of Child and Adolescent Psychiatry The Children’s Hospital of Philadelphia Philadelphia Pennsylvania USA

3. Department of Biobehavioral Health Sciences University of Pennsylvania School of Nursing Philadelphia Pennsylvania USA

4. Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

Funder

Novo Nordisk UK Research Foundation

Publisher

Wiley

Subject

Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/oby.22359

Reference40 articles.

1. Mechanisms, Pathophysiology, and Management of Obesity

2. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on practice guidelines. Based on a systematic review from The Obesity Expert Panel, 2013;Jensen MD;Obesity (Silver Spring),2014

3. Centers for Medicare and Medicaid Services.Decision memo for intensive behavioral therapy for obesity (CAG‐00423N). Published2015. (https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&NcaName=Intensive%20Behavioral%20Therapy%20for%20Obesity&bc=ACAAAAAAIAAA&NCAId=253. Published November 29 2011.

4. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement;Moyer VA;Ann Intern Med,2012

5. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review;eClinicalMedicine;2024-09

2. Super response to liraglutide in people with obesity: A case report and literature review;Endocrinología, Diabetes y Nutrición;2024-08

3. OS EFEITOS COLATERAIS DOS ANÁLOGOS DE GLP-1 EM INDIVÍDUOS NÃO DIABÉTICOS: UMA REVISÃO INTEGRATIVA DA LITERATURA;Revista Contemporânea;2024-07-05

4. Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial;The Lancet Regional Health - Europe;2024-04

5. Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression;Diabetes, Obesity and Metabolism;2024-03-20